Dr. Jon Odorico

Founder, Lead Researcher (likely CSO or similar)

Therapeutic Areas

Drug	Indication	Phase
iPSC-Derived Islet Cell Therapy	Type 1 and Type 2 Diabetes	Clinical Trials (phase unspecified)